Evaluation of transrectal ultrasound-guided tru-cut biopsy as a complementary method for predicting pathological complete response in rectal cancer after neoadjuvant treatment: a phase II prospective and diagnostic trial

Author:

Huang Yaoyi123,Xie Yumo123,Wang Puning123,Chen Yao4,Qin Si4,Li Fangqian5,Wu Yuanhui123,Huang Mingzhe123,Hou Zehui123,Cai Yonghua123,He Xiaosheng123,Lin Hongcheng123,Hu Bang123,Qin Qiyuan123,Ma Tenghui123,Tan Shuyun123,Liao Yi123,Ke Jia123,Zhang Di123,Lai Sicong123,Jiang ZhiPeng123,Wang Huaiming,Xiang Jun123,Cai Zerong123,Wang Hui123,He Xiaowen123,Yang Zuli123,Ren Donglin123,Wu Xiaojian123,Hong Yisong123,Huang Meijin123,Luo Yanxin123,Liu Guangjian4,Lin Jinxin123ORCID

Affiliation:

1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen, University, Guangzhou, Guangdong, China

2. Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China

3. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

4. Department of Medical Ultrasonics, The Sixth Affiliated Hospital, Sun Yat-sen, University, Guangzhou, Guangdong, China

5. Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Abstract

Importance: Patients with pCR of rectal cancer following neoadjuvant treatment had better oncological outcomes. However, reliable methods for accurately predicting pCR remain limited. Objective: To evaluate whether transrectal ultrasound-guided tru-cut biopsy (TRUS-TCB) adds diagnostic value to conventional modalities for predicting pathological complete response (pCR) in patients with rectal cancer after neoadjuvant treatment. Design, Setting, and Participants: This study evaluated data of patients with rectal cancer who were treated with neoadjuvant treatment and reassessed using TRUS-TCB and conventional modalities before surgery. This study is registered with ClinicalTrials.gov. Main Outcomes and Measures: The primary outcome was accuracy, along with secondary outcomes including sensitivity, specificity, negative predictive value, and positive predictive value in predicting tumor residues. Final surgical pathology was used as reference standard. Results: Between June 2021 and June 2022, a total of 74 patients were enrolled, with 63 patients ultimately evaluated. Among them, 17 patients (28%) exhibited a complete pathological response. TRUS-TCB demonstrated an accuracy of 0.71 (95% CI, 0.58-0.82) in predicting tumor residues. The combined use of TRUS-TCB and conventional modalities significantly improved diagnostic accuracy compared to conventional modalities alone (0.75 vs. 0.59, P=0.02). Furthermore, TRUS-TCB correctly reclassified 52% of patients erroneously classified as having a complete clinical response by conventional methods. The occurrence of only one mild adverse event was observed. Conclusions and Relevance: Transrectal ultrasound-guided tru-cut biopsy (TRUS-TCB) proves to be a safe and accessible tool for reevaluation with minimal complications. The incorporation of TRUS-TCB alongside conventional methods leads to enhanced diagnostic performance.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3